Adalimumab Biosimilar Switch Receives High Acceptance in IBD
, 2025-04-30 12:00:00 TOPLINE: More than 90% of patients with inflammatory bowel disease (IBD) accepted the switch from the adalimumab reference product to adalimumab biosimilars, with favourable survival and remission outcomes and a positive patient experience at 12 months. A poor opinion of generic drugs was associated with the refusal to switch. METHODOLOGY: Researchers conducted…